MX2022010217A - Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma. - Google Patents
Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma.Info
- Publication number
- MX2022010217A MX2022010217A MX2022010217A MX2022010217A MX2022010217A MX 2022010217 A MX2022010217 A MX 2022010217A MX 2022010217 A MX2022010217 A MX 2022010217A MX 2022010217 A MX2022010217 A MX 2022010217A MX 2022010217 A MX2022010217 A MX 2022010217A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- pharmaceutical composition
- composition containing
- containing anti
- histidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporciona una composición farmacéutica que contiene un anticuerpo anti-IL-4R y el uso del mismo. La composición farmacéutica contiene un anticuerpo anti-IL-4R o un fragmento de unión a antígeno del mismo en un agente amortiguador de ácido acético-histidina, un modificador de la viscosidad, un tensioactivo y un estabilizador.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010107765 | 2020-02-21 | ||
CN202110145455 | 2021-02-02 | ||
PCT/CN2021/076854 WO2021164728A1 (zh) | 2020-02-21 | 2021-02-19 | 一种抗il-4r抗体药物组合物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022010217A true MX2022010217A (es) | 2022-09-19 |
Family
ID=77390440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022010217A MX2022010217A (es) | 2020-02-21 | 2021-02-19 | Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230088052A1 (es) |
EP (1) | EP4104858A4 (es) |
JP (1) | JP2023515423A (es) |
KR (1) | KR20220143882A (es) |
CN (1) | CN114980926A (es) |
AU (1) | AU2021223128A1 (es) |
BR (1) | BR112022016345A2 (es) |
CA (1) | CA3169959A1 (es) |
MX (1) | MX2022010217A (es) |
TW (1) | TW202139974A (es) |
WO (1) | WO2021164728A1 (es) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
DK2990420T3 (en) | 2000-05-26 | 2017-04-03 | Immunex Corp | USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
ES2859825T3 (es) | 2006-10-02 | 2021-10-04 | Regeneron Pharma | Anticuerpos humanos con alta afinidad para el receptor IL-4 humano |
EA028945B1 (ru) * | 2010-10-06 | 2018-01-31 | Ридженерон Фармасьютикалз, Инк. | СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К АЛЬФА РЕЦЕПТОРУ ЧЕЛОВЕЧЕСКОГО ИНТЕРЛЕЙКИНА-4 (hIL-4Rα) |
HUE064945T2 (hu) | 2012-08-21 | 2024-04-28 | Sanofi Biotechnology | Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával |
AU2015310879A1 (en) | 2014-09-03 | 2017-03-02 | Medimmune Limited | Stable anti-IL-4R-alpha antibody formulation |
CN111686247B (zh) * | 2019-03-13 | 2022-07-29 | 苏州康乃德生物医药有限公司 | 包含人白介素-4受体α的抗体的液体组合物 |
CN114652853A (zh) * | 2020-12-22 | 2022-06-24 | 江苏恒瑞医药股份有限公司 | 抗il-4r抗体-药物偶联物及医药用途 |
-
2021
- 2021-02-19 CN CN202180009420.4A patent/CN114980926A/zh active Pending
- 2021-02-19 KR KR1020227031858A patent/KR20220143882A/ko unknown
- 2021-02-19 US US17/800,868 patent/US20230088052A1/en active Pending
- 2021-02-19 JP JP2022549280A patent/JP2023515423A/ja active Pending
- 2021-02-19 TW TW110105766A patent/TW202139974A/zh unknown
- 2021-02-19 MX MX2022010217A patent/MX2022010217A/es unknown
- 2021-02-19 CA CA3169959A patent/CA3169959A1/en active Pending
- 2021-02-19 AU AU2021223128A patent/AU2021223128A1/en active Pending
- 2021-02-19 EP EP21757185.0A patent/EP4104858A4/en active Pending
- 2021-02-19 BR BR112022016345A patent/BR112022016345A2/pt unknown
- 2021-02-19 WO PCT/CN2021/076854 patent/WO2021164728A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021164728A1 (zh) | 2021-08-26 |
EP4104858A1 (en) | 2022-12-21 |
AU2021223128A1 (en) | 2022-09-08 |
CA3169959A1 (en) | 2021-08-26 |
EP4104858A4 (en) | 2023-11-29 |
JP2023515423A (ja) | 2023-04-13 |
CN114980926A (zh) | 2022-08-30 |
BR112022016345A2 (pt) | 2022-12-20 |
KR20220143882A (ko) | 2022-10-25 |
US20230088052A1 (en) | 2023-03-23 |
TW202139974A (zh) | 2021-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008219A (es) | Formulacion farmaceutica de ph bajo. | |
PH12018501419A1 (en) | Pharmaceutical composition comprising bispecific antibody constructs | |
CY1123657T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
AU2018267843A1 (en) | PD-L1 antibody pharmaceutical composition and use thereof | |
WO2018222722A3 (en) | COMPOSITIONS COMPRISING ANTI-LAG-3 ANTIBODY OR ANTI-LAG-3 ANTIBODY AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY | |
CO5720212A1 (es) | Composicion de anticuerpo her2 | |
MX2021005018A (es) | Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma. | |
JOP20190189A1 (ar) | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t | |
WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
EP4067387A4 (en) | BISPECIFIC ANTI-PD-1 ANTI-VEGFA NTIBODY, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
MX2022011770A (es) | Composicion farmaceutica que contiene un conjugado de anticuerpo-farmaco y uso de la misma. | |
JOP20220030A1 (ar) | صيغ مضادة لـ c5 عالية التركيز | |
MX2020009935A (es) | Formulaciones acuosas y estables de anticuerpos anti-tau. | |
CL2023000486A1 (es) | Formulación farmacéutica que comprende un bite, anticuerpo biespecífico y metionina | |
MX2022014161A (es) | Vacunas contra sars-cov-2. | |
MX2023008423A (es) | Anticuerpos anti-gremlin1 novedosos. | |
CL2020001307A1 (es) | Formulación. | |
MX2020000582A (es) | Composicion farmaceutica de anticuerpos sost y usos de la misma. | |
MX2021010254A (es) | Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos. | |
MX2022010217A (es) | Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma. | |
MX2019014666A (es) | Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo. | |
MX2021011530A (es) | Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso. | |
MX2023009971A (es) | Composicion farmaceutica que contiene anticuerpo anti-tslp. | |
BR112023002926A2 (pt) | Agentes terapêuticos inaláveis | |
MX2022007960A (es) | Nuevos anticuerpos anti-fgfr2b. |